
Vassiliki A Boussiotis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4293270/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunology, 2001, 2, 261-268.	7.0	2,504
2	Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. New England Journal of Medicine, 2016, 375, 1767-1778.	13.9	1,025
3	PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nature Communications, 2015, 6, 6692.	5.8	834
4	Reconstructing and Deconstructing Agonist-Induced Activation of Integrin αIIbβ3. Current Biology, 2006, 16, 1796-1806.	1.8	419
5	Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation. Science Signaling, 2012, 5, ra46.	1.6	411
6	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Frontiers in Immunology, 2016, 7, 550.	2.2	409
7	Maintenance of Human T Cell Anergy: Blocking of IL-2 Gene Transcription by Activated Rap1. Science, 1997, 278, 124-128.	6.0	408
8	RIAM, an Ena/VASP and Profilin Ligand, Interacts with Rap1-GTP and Mediates Rap1-Induced Adhesion. Developmental Cell, 2004, 7, 585-595.	3.1	382
9	Lamellipodin, an Ena/VASP Ligand, Is Implicated in the Regulation of Lamellipodial Dynamics. Developmental Cell, 2004, 7, 571-583.	3.1	301
10	Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Science Immunology, 2020, 5, .	5.6	287
11	Revisiting the PD-1 pathway. Science Advances, 2020, 6, .	4.7	277
12	T cell anergy and costimulation. Immunological Reviews, 2003, 192, 161-180.	2.8	255
13	Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nature Immunology, 2001, 2, 1174-1182.	7.0	250
14	The role of peroxisome proliferator-activated receptors (PPAR) in immune responses. Metabolism: Clinical and Experimental, 2021, 114, 154338.	1.5	229
15	p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nature Medicine, 2000, 6, 290-297.	15.2	216
16	CD28 Costimulation Mediates Down-Regulation of p27 <i>kip1</i> and Cell Cycle Progression by Activation of the PI3K/PKB Signaling Pathway in Primary Human T Cells. Journal of Immunology, 2002, 168, 2729-2736.	0.4	187
17	CD28 Costimulation Mediates T Cell Expansion Via IL-2-Independent and IL-2-Dependent Regulation of Cell Cycle Progression. Journal of Immunology, 2000, 164, 144-151.	0.4	178
18	The Role of B7-1/B7-2:CD28/CLTA-4 Pathways in the Prevention of Anergy, Induction of Productive Immunity and Down-Regulation of the Immune Response. Immunological Reviews, 1996, 153, 5-26.	2.8	153

#	Article	IF	CITATIONS
19	Umbilical cord blood transplantation: Basic biology and clinical challenges to immune reconstitution. Clinical Immunology, 2008, 127, 286-297.	1.4	153
20	PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2. Molecular and Cellular Biology, 2013, 33, 3091-3098.	1.1	152
21	Biochemical Signaling of PD-1 on T Cells and Its Functional Implications. Cancer Journal (Sudbury,) Tj ETQq1 1 (0.784314 r 1.0	$gBT_{146}/Overlock$
22	Mechanisms and consequences of agonist-induced talin recruitment to platelet integrin αIIbβ3. Journal of Cell Biology, 2008, 181, 1211-1222.	2.3	145
23	Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Science Translational Medicine, 2016, 8, 368ra171.	5.8	140
24	CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood, 2005, 106, 3068-3073.	0.6	129
25	Ex Vivo Generation of Human Anti–Pre-B Leukemia-Specific Autologous Cytolytic T Cells. Blood, 1997, 90, 549-561.	0.6	125
26	Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy. Frontiers in Oncology, 2018, 8, 237.	1.3	123
27	Immunotherapies for malignant glioma. Oncogene, 2018, 37, 1121-1141.	2.6	108
28	Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood, 2010, 115, 4111-4119.	0.6	107
29	PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. Cell Cycle, 2012, 11, 4305-4309.	1.3	103
30	A pathway regulated by cell cycle inhibitor p27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance. Nature Immunology, 2006, 7, 1157-1165.	7.0	96
31	IL-1β–Mediated Signals Preferentially Drive Conversion of Regulatory T Cells but Not Conventional T Cells into IL-17–Producing Cells. Journal of Immunology, 2010, 185, 4148-4153.	0.4	95
32	A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunology, Immunotherapy, 2019, 68, 421-432.	2.0	93
33	Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation. Communications Biology, 2020, 3, 128.	2.0	91
34	Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression. Nature Immunology, 2022, 23, 971-984.	7.0	79
35	The role of IL-17-producing Foxp3+ CD4+ T cells in inflammatory bowel disease and colon cancer. Clinical Immunology, 2013, 148, 246-253.	1.4	70
36	Regulation of T Cell Differentiation and Function by EZH2. Frontiers in Immunology, 2016, 7, 172.	2.2	70

#	Article	IF	CITATIONS
37	Clinical significance of T cell metabolic reprogramming in cancer. Clinical and Translational Medicine, 2016, 5, 29.	1.7	69
38	The role of the thymus in T-cell immune reconstitution after umbilical cord blood transplantation. Blood, 2014, 124, 3201-3211.	0.6	63
39	Rap1-interacting adapter molecule (RIAM) associates with the plasma membrane via a proximity detector. Journal of Cell Biology, 2012, 199, 317-329.	2.3	54
40	Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses. Frontiers in Immunology, 2017, 8, 330.	2.2	44
41	Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2. Oncotarget, 2016, 7, 85624-85640.	0.8	44
42	CD134-Allodepletion Allows Selective Elimination of Alloreactive Human T Cells without Loss of Virus-Specific and Leukemia-Specific Effectors. Biology of Blood and Marrow Transplantation, 2008, 14, 518-530.	2.0	43
43	Somatic Mutations and Immunotherapy Outcome with CTLA-4 Blockade in Melanoma. New England Journal of Medicine, 2014, 371, 2230-2232.	13.9	43
44	The adaptor molecule RIAM integrates signaling events critical for integrin-mediated control of immune function and cancer progression. Science Signaling, 2017, 10, .	1.6	39
45	Runx1 and Runx3 Are Involved in the Generation and Function of Highly Suppressive IL-17-Producing T Regulatory Cells. PLoS ONE, 2012, 7, e45115.	1.1	37
46	RIAM (Rap1-interacting adaptor molecule) regulates complement-dependent phagocytosis. Cellular and Molecular Life Sciences, 2013, 70, 2395-2410.	2.4	36
47	Rap1-GTP-interacting Adaptor Molecule (RIAM) Protein Controls Invasion and Growth of Melanoma Cells. Journal of Biological Chemistry, 2011, 286, 18492-18504.	1.6	35
48	Rap1-GTP Is a Negative Regulator of Th Cell Function and Promotes the Generation of CD4+CD103+ Regulatory T Cells In Vivo. Journal of Immunology, 2005, 175, 3133-3139.	0.4	33
49	Tob, a member of the APRO family, regulates immunological quiescence and tumor suppression. Cell Cycle, 2009, 8, 1019-1025.	1.3	31
50	The cyclin dependent kinase inhibitor (R)-roscovitine prevents alloreactive T cell clonal expansion and protects against acute GvHD. Cell Cycle, 2009, 8, 1794-1802.	1.3	30
51	CD28 Costimulation Mediates Transcription of SKP2 and CKS1, the Substrate Recognition Components of SCFSkp2 Ubiquitin Ligase That Leads p27kip1 to Degradation. Cell Cycle, 2006, 5, 2123-2129.	1.3	29
52	RIAM Regulates the Cytoskeletal Distribution and Activation of PLC-Î ³ 1 in T Cells. Science Signaling, 2009, 2, ra79.	1.6	29
53	The role of metabolic reprogramming in T cell fate and function. Current Trends in Immunology, 2016, 17, 1-12.	4.0	29
54	Molecular and functional heterogeneity of T regulatory cells. Clinical Immunology, 2011, 141, 244-252.	1.4	28

#	Article	IF	CITATIONS
55	Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications. Journal of Molecular Medicine, 2006, 84, 887-899.	1.7	24
56	PD-1+ Treg cells: a foe in cancer immunotherapy?. Nature Immunology, 2020, 21, 1311-1312.	7.0	24
5 7	Rap1 Regulation of RIAM and Cell Adhesion. Methods in Enzymology, 2006, 407, 345-358.	0.4	23
58	Blockade of 6-phosphogluconate dehydrogenase generates CD8+ effector TÂcells with enhanced anti-tumor function. Cell Reports, 2021, 34, 108831.	2.9	23
59	IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults. PLoS ONE, 2015, 10, e0132564.	1.1	22
60	The PDâ€∃ Interactome. Advanced Biology, 2021, 5, e2100758.	1.4	21
61	Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vsHost Disease. Frontiers in Immunology, 2019, 10, 295.	2.2	20
62	Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells. Scientific Reports, 2019, 9, 17252.	1.6	20
63	Rap1A regulates generation of T regulatory cells via LFA-1-dependent and LFA-1-independent mechanisms. Cellular Immunology, 2010, 266, 7-13.	1.4	16
64	T Cell Metabolism in Cancer Immunotherapy. Immunometabolism, 2020, 2, .	0.7	16
65	Twisted gastrulation (Tsg) is regulated by Tob and enhances TGF-β signaling in activated T lymphocytes. Blood, 2007, 109, 2944-2952.	0.6	14
66	The cyclin dependent kinase inhibitor (R)-roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors. Clinical Immunology, 2014, 152, 48-57.	1.4	13
67	Possible reactivation of chromosomally integrated human herpesvirus 6 after treatment with histone deacetylase inhibitor. Blood Advances, 2018, 2, 1367-1370.	2.5	13
68	Active Rap1, a small GTPase that induces malignant transformation of hematopoietic progenitors, localizes in the nucleus and regulates protein expression. Leukemia and Lymphoma, 2007, 48, 987-1002.	0.6	12
69	R24 anti-GD3 ganglioside antibody can induce co-stimulation and prevent the induction of alloantigen-specific T cell clonal anergy. European Journal of Immunology, 1996, 26, 2149-2154.	1.6	11
70	Cell-specific PD-L1 expression in DLBCL. Blood, 2015, 126, 2171-2172.	0.6	11
71	Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells. Clinical Immunology, 2019, 207, 18-23.	1.4	10
72	Effects of PD-1 Signaling on Immunometabolic Reprogramming. Immunometabolism, 2022, 4, .	0.7	10

5

#	Article	IF	CITATIONS
73	BK polyomavirus reactivation after reduced-intensity double umbilical cord blood cell transplantation. Transplant Immunology, 2015, 32, 116-120.	0.6	7
74	Clinical Trial Evaluating DC/AML Fusion Cell Vaccination In AML Patients. Blood, 2013, 122, 3928-3928.	0.6	7
75	Phosphorylation of Tyrosine 340 in the Plekstrin Homology Domain of RIAM Is Required for Translocation of RIAM to the Plasma Membrane, Phosphorylation of RIAM-Associated PLC-g1 and LFA-1 Activation. Blood, 2014, 124, 2743-2743.	0.6	5
76	JAK3-mediated phosphorylation of EZH2: a novel mechanism of non-canonical EZH2 activation and oncogenic function. Translational Cancer Research, 2016, 5, S1208-S1211.	0.4	5
77	Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. Biology of Blood and Marrow Transplantation, 2017, 23, 103-112.	2.0	4
78	A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplantation, 2020, 55, 804-810.	1.3	3
79	Structural, biochemical, and functional properties of the Rap1-Interacting Adaptor Molecule (RIAM). Biomedical Journal, 2021, , .	1.4	3
80	Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission. Blood, 2011, 118, 948-948.	0.6	3
81	Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation. Blood, 2012, 120, 578-578.	0.6	3
82	PD-1 Inhibits TCR Proximal Signaling By Sequestering SHP-2 Phosphatase and Facilitating Csk-Mediated Inhibitory Phosphorylation of Lck. Blood, 2015, 126, 283-283.	0.6	3
83	Feeling stressed? It might be your T cells. Nature Immunology, 2017, 18, 1281-1283.	7.0	2
84	Unraveling Key Players of Humoral Immunity: Advanced and Optimized Lymphocyte Isolation Protocol from Murine Peyer's Patches. Journal of Visualized Experiments, 2018, , .	0.2	2
85	Metabolic Reprogramming of Myeloid Cells in Response to Factors of "Emergency" Myelopoiesis By Myeloid-Specific PD-1 Ablation, Regulates Myeloid Lineage Fate Commitment and Anti-Tumor Immunity. Blood, 2018, 132, 14-14.	0.6	2
86	Rap1-GTP Promotes the Generation of Regulatory T Cells in Vivo Blood, 2004, 104, 110-110.	0.6	2
87	The E3 Ubiquitin Ligase TRIM36, a Transcriptional Target of Tob, Is Expressed in Anergic T Cells and Mediates Unresponsiveness through Proteolysis of Signaling Proteins PLC- γ1 and PKC-? Blood, 2004, 104, 113-113.	0.6	2
88	Dendritic Cell Tumor Fusion Vaccination in Conjunction with Autologous Transplantation for Multiple Myeloma Blood, 2009, 114, 783-783.	0.6	2
89	Commentary on: Combination of Metabolic Intervention and T Cell Therapy Enhances Solid Tumor Immunotherapy. Immunometabolism, 2021, 3, .	0.7	2
90	Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation. Bone Marrow Transplantation, 2020, 55, 1821-1823.	1.3	1

#	Article	IF	CITATIONS
91	Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T Cells. Blood, 2019, 134, 3275-3275.	0.6	1
92	Effects of Cord Blood Cell Subset Populations in the Development of the Dominant Cord Blood Unit in Non-Myeloablative Sequential Double Cord Blood Transplantation (DCBT) Blood, 2006, 108, 3148-3148.	0.6	1
93	Targeting Acute Myeloid Leukemia Stem Cells by MUC1-C Subunit Inhibition. Blood, 2010, 116, 848-848.	0.6	1
94	Interaction of Both SH2 Domains of SHP-2 with a PD-1 Homodimer Is Required for PD-1-Mediated Inhibition of T Cell Responses. Blood, 2016, 128, 859-859.	0.6	1
95	CD4+CD25+ Regulatory T Cells from Cord Blood Have Functional and Molecular Properties of T Cell Anergy Blood, 2004, 104, 316-316.	0.6	1
96	The Rap1-RIAM Pathway Regulates the Expression of Integrins αEβ7(CD103) and α4β7, Which Guide T Cell Homing to Intestinal Compartments. Blood, 2018, 132, 864-864.	0.6	1
97	Flow Cytometric Analysis for Identification of the Innate and Adaptive Immune Cells of Murine Lung. Journal of Visualized Experiments, 2021, , .	0.2	1
98	Pparα Ablation Suppresses T Cell Responses and Anti-Tumor Immunity By Compromising the Antigen-Presenting Properties of Tumor-Associated Macrophages. Blood, 2021, 138, 438-438.	0.6	1
99	IMMU-31. DRIVER GENE MUTATIONS DICTATE THE COMPOSITION OF THE IMMUNE LANDSCAPE OF GLIOBLASTOMA AND CONFER SELECTIVE RESPONSE TO IMMUNOTHERAPY. Neuro-Oncology, 2019, 21, vi125-vi125.	0.6	0
100	RIAM, a New Rap1 Effector, Functions Downstream of Rap1 and Regulates Rap1 Localization at the Plasma Membrane and Rap1-Induced Adhesion Blood, 2004, 104, 510-510.	0.6	0
101	RIAM Regulate Spatio-Temporal Distribution of PLC-Î ³ 1 and Calcium Mobilization during T Cell Activation. Blood, 2008, 112, 673-673.	0.6	0
102	Development of CMV-SPECIFIC Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of NAII^VE CD8+ T Cells. Blood, 2008, 112, 1167-1167.	0.6	0
103	Roscovitine Prevents Alloreactive T Cell Expansion and TNF-a-Mediated Proinflammatory Gene Expression and Protects against GvHD Blood, 2008, 112, 2341-2341.	0.6	0
104	RIAM and RapL Regulate Distinct Signaling Events and Functional Outcomes Upon TCR-Mediated Activation Blood, 2009, 114, 3683-3683.	0.6	0
105	Rap1-GTP Augments Activation of Smad and p38 Mediated Signaling Downstream of TGF-β Receptor In T Lymphocytes. Blood, 2010, 116, 956-956.	0.6	0
106	RIAM. The AFCS-nature Molecule Pages, 0, , .	0.2	0
107	Addition of Clofarabine to TLI/ATG Conditioning: Impact on Immune Reconstitution and Clinical Outcomes,. Blood, 2011, 118, 4066-4066.	0.6	0
108	Immune Reconstitution After Cord Blood Transplantation in Adults Depends on Activity of Thymic Epithelial Cells and Vascular Endothelial Elements,. Blood, 2011, 118, 4075-4075.	0.6	0

#	Article	IF	CITATIONS
109	Targeting Leukemia Initiating Cells by MUC1-C Subunit Inhibition. Blood, 2012, 120, 3583-3583.	0.6	0
110	BK Virus Reactivation After Double Umbilical Cord Blood Transplantation in Adults Correlates with Tregs and Delayed Reconstitution of CD4+ and CD8+ T Effector Cells. Blood, 2012, 120, 4174-4174.	0.6	0
111	Inhibition Of Cdk2 Promotes The Generation Of Inducible CD8+ T Regulatory Cells By Modulating The Epigenetic Regulator EZH2. Blood, 2013, 122, 138-138.	0.6	0
112	Prognostic Value of TREC, IL-7 and SCF Levels on Clinical Outcomes after Double Umbilical Cord Blood Transplantation in Adults. Blood, 2014, 124, 2488-2488.	0.6	0
113	Delayed Platelet Engraftment after Umbilical Cord Blood Transplant: Relationship to Circulating Levels of Thrombopoietin. Blood, 2014, 124, 3862-3862.	0.6	0
114	RIAM Interacts with the Hematopoietic-Specific Adaptor Protein Gads and Forms a LAT-Independent Node of Signal Integration That Regulates Activation of PLC-Î ³ 1. Blood, 2014, 124, 4138-4138.	0.6	0
115	Rap1-GTP Augments TGF-b-Mediated Signaling in T Lymphocytes Via a Mechanism Dependent on the b Chain of LFA-1 Integrin. Blood, 2015, 126, 3422-3422.	0.6	0
116	RIAM (Rap1-Interactive Adaptor Molecule). , 2016, , 1-10.		0
117	Prostaglandin E2 Alters the Differentiation and Function of Antigen-Specific T Cells By Targeting the Metabolic Gene Regulatory Network Downstream of mTORC1. Blood, 2016, 128, 552-552.	0.6	0
118	RIAM (Rap1-Interactive Adaptor Molecule). , 2018, , 4700-4709.		0
119	The Two SH2 Domains of SHP-2 Bridge Two PD-1 Molecules Resulting in SHP-2 Activation and PD-1-Mediated Inhibition. Blood, 2018, 132, 862-862.	0.6	0
120	Myeloid-Specific SHP-2 Ablation Induces Robust Anti-Tumor Immunity That Is Not Further Enhanced By PD-1 Blockade. Blood, 2020, 136, 25-26.	0.6	0